[1] Du Y, Zhang J, Wu LJ, et al. The epidemiology, diagnosis and prognosis of long-COVID. Biomed Environ Sci, 2022; 35, 1133−9.
[2] Ma Y, Mishra SR, Han XK, et al. The relationship between time to a high COVID-19 response level and timing of peak daily incidence: an analysis of governments' Stringency Index from 148 countries. Infect Dis Poverty, 2021; 10, 96. doi:  10.1186/s40249-021-00880-x
[3] Coccia M. Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis. Environ Res, 2022; 204, 112314. doi:  10.1016/j.envres.2021.112314
[4] Wang JY, Zong XY, Wu GH, et al. 3- to 24-month follow-up on COVID-19 with pulmonary tuberculosis survivors after discharge: results from a prospective, multicenter study. Biomed Environ Sci, 2022; 35, 1091−9.
[5] Ji YL, Wu Y, Qiu Z, et al. The pathogenesis and treatment of COVID-19: a system review. Biomed Environ Sci, 2021; 34, 50−60.
[6] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Wkly, 2020; 2, 113−22. doi:  10.46234/ccdcw2020.032
[7] Ma Y, Zhu DS, Chen RB, et al. Association of overlapped and un-overlapped comorbidities with COVID-19 severity and treatment outcomes: a retrospective cohort study from nine provinces in China. Biomed Environ Sci, 2020; 33, 893−905.
[8] Pepera G, Tribali MS, Batalik L, et al. Epidemiology, risk factors and prognosis of cardiovascular disease in the Coronavirus Disease 2019 (COVID-19) pandemic era: a systematic review. Rev Cardiovasc Med, 2022; 23, 28.
[9] Qian Z, Li ZH, Peng J, et al. Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis. Clin Exp Hypertens, 2022; 44, 451−8. doi:  10.1080/10641963.2022.2071914
[10] Wang JY, Zong XY, Wu GH, et al. 3- to 24-month follow-up on COVID-19 with pulmonary tuberculosis survivors after discharge: results from a prospective, multicenter study. Biomed Environ Sci, 2022; 35, 1091−9.
[11] Chen Z, Peng YY, Wu XL, et al. Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: a systematic review and meta-analysis. Front Public Health, 2022; 10, 923485. doi:  10.3389/fpubh.2022.923485
[12] Dash SK, Jena L, Panigrahy R, et al. Brucella melitensis lurking threat in eastern part of Odisha - a case report. J Pure Appl Microbiol, 2022; 16, 2949−53. doi:  10.22207/JPAM.16.4.12
[13] Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. Lancet Infect Dis, 2006; 6, 91−9. doi:  10.1016/S1473-3099(06)70382-6
[14] Godfroid J, Cloeckaert A, Liautard JP, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res, 2005; 36, 313−26. doi:  10.1051/vetres:2005003
[15] Madzingira O, Fasina OF, Kalinda C, et al. Seroprevalence of brucellosis among clinically suspected human cases presenting at health facilities in Namibia from 2012 to 2017. Biomed Environ Sci, 2021; 34, 232−5.
[16] Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia—10 years of clinical experience in endemic region. Croat Med J, 2010; 51, 327−36. doi:  10.3325/cmj.2010.51.327
[17] Pappas G. The peculiar ways of Brucella survival: looking through the keyhole. Virulence, 2010; 1, 473−4. doi:  10.4161/viru.1.6.13200
[18] Ariza J, Pigrau C, Cañas C, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis, 2001; 32, 1024−33. doi:  10.1086/319608
[19] Young EJ. An overview of human brucellosis. Clin Infect Dis, 1995; 21, 283−90. doi:  10.1093/clinids/21.2.283
[20] Shabani S, Ghadimi S. COVID-19 co-infection in a patient with brucellosis. Clin Case Rep, 2022; 10, e6367.
[21] Güven M. Brucellosis in a patient diagnosed with Coronavirus Disease 2019 (COVID-19). J Infect Dev Ctries, 2021; 15, 1104−6. doi:  10.3855/jidc.13899
[22] Kucuk GO, Gorgun S. Brucellosis mimicking COVID-19: a point of view on differential diagnosis in patients with fever, dry cough, arthralgia, and hepatosplenomegaly. Cureus, 2021; 13, e15848.
[23] National Health Commission of the People's Republic of China. Diagnosis of Brucellosis (WS 269-2019). http://www.nhc.gov.cn/wjw/s9491/201905/b109b71e7a624256985b573944b5d292.shtml. [2023-01-10]. (In Chinese)
[24] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009; 6, e1000097. doi:  10.1371/journal.pmed.1000097
[25] Yang Y, Duan BF, Dong GD, et al. Research progress on brucellosis in human and animals. China Anim Health Inspec, 2020; 37, 76−83.
[26] Han Q, Zheng B, Daines L, et al. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens, 2022; 11, 269. doi:  10.3390/pathogens11020269
[27] Wang N, Yang MB, Yang PY, et al. A case series of olfactory dysfunction in imported COVID-19 patients: a 12-month follow-up study. Biomed Environ Sci, 2022; 35, 402−11.
[28] Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol, 2021; 12, 698169. doi:  10.3389/fmicb.2021.698169
[29] Adeloye D, Elneima O, Daines L, et al. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med, 2021; 9, 1467−78. doi:  10.1016/S2213-2600(21)00286-1
[30] Huang LX, Yao Q, Gu XY, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet, 2021; 398, 747−58. doi:  10.1016/S0140-6736(21)01755-4
[31] Yang XY, Hou C, Shen Y, et al. Two-year health outcomes in hospitalized COVID-19 survivors in China. JAMA Netw Open, 2022; 5, e2231790. doi:  10.1001/jamanetworkopen.2022.31790
[32] Barreto-Argilagos GA, De La Caridad Rodríguez-Torrens H. At least one zoonosis silently spreads during COVID-19: brucellosis. MEDICC Rev, 2021; 23, 8.
[33] Franco MP, Mulder M, Smits HL. Persistence and relapse in brucellosis and need for improved treatment. Trans R Soc Trop Med Hyg, 2007; 101, 854−5. doi:  10.1016/j.trstmh.2007.05.016
[34] Hoang T. Characteristics of COVID-19 recurrence: a systematic review and meta-analysis. Ann Glob Health, 2021; 87, 28. doi:  10.5334/aogh.3163